Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00796809

Enrollment

598

Registered

2008-11-24

Start date

2007-10-31

Completion date

2008-10-31

Last updated

2015-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coccidioidomycosis, Rheumatoid Arthritis

Keywords

TNF inhibitors, Biologic agents, coccidioidomycosis, Rheumatoid arthritis

Brief summary

The goal of the project is to study the risk of coccidioidomycosis (valley fever) in patients receiving anti-TNF and other biologic agents for inflammatory arthritis in Tucson, Arizona.

Detailed description

Retrospective chart review of all patients with an inflammatory arthritis seen at the University Rheumatology clinic since January 2000.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* All active patients with an inflammatory arthritis seen at the University of Arizona from January 2000

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
Determine the incidence rate and calculate the risk of coccidioidomycosis in patients receiving various anti-TNF agents or other biologics, and patients not receiving these agents for their inflammatory arthritis	one year

Secondary

Measure	Time frame
To calculate the incidence density of coccidioidomycosis cases in patients receiving each drug.	One year
To compare number of disseminated cases of coccidioidomycosis in each group	One year

Countries

United States

Outcome results